Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE™ Platform Funding will accelerate company growth and infrastructure expansion leading up to full commercial launch CAMBRIDGE, Mass., April 7, 2021-- Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures. Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund.